drugset / Trial / NCT00527540
Effectiveness and Side Effects of Pegylated Interferon Alpha-2a (Pegaferon®) Plus Ribavirin in the Patients With Chronic Hepatitis C
Phase 3
Completed
60 enrolled
Tehran Hepatitis Center
Kermanshah University of Medical Sciences · collab
NaSingle-groupOpen-labelTreatment
Summary
Pegylation of interferon prolongs the medication half-life which has resulted in Pegylated Interferon (PEG-IFN) as the new modality for treatment of chronic hepatitis C. We current this clinical trial to assess the efficacy and safety of domestic PEG-IFN alpha-2a (Pegaferon®) in the patients with chronic hepatitis C.
Timeline
- Start
- 2007-02
- Primary completion
- 2008-06
- Completion
- 2008-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2a | Protein / enzyme biologic | 180 ug | — |
| Background | Ribavirin | Small molecule | 10 mg/kg | — |
| Background | Ribavirin | Small molecule | 15 mg/kg | — |